Mitral Valve Disease Market Report 2026
Global Outlook – By Treatment Type (Mitral Valve Repair, Mitral Valve Replacement, Mitral Valve Therapeutics), By Indication (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End-User (Hospitals, Ambulatory Surgical Centers, Other End-Users) - Market Size, Trends, Strategies, and Forecast to 2030
Mitral Valve Disease Market Overview
• Mitral Valve Disease market size has reached to $3.28 billion in 2025 • Expected to grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Impact Of Rising Prevalence Of Vascular Heart Diseases On The Mitral Valve Disease Market • Market Trend: Advancing Mitral Valve Disease Care With Innovative Treatment Technologies • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Mitral Valve Disease Market?
Mitral valve disease is a disorder impacting the mitral valve, which controls blood movement between the heart's left atrium and left ventricle. It can result in the valve becoming narrowed or leaky, disrupting normal blood flow and causing issues like breathlessness, tiredness, and abnormal heart rhythms. The primary aim of managing mitral valve disease is to ensure proper blood flow through the heart and to prevent complications. The main treatments of mitral valve disease include mitral valve repair, mitral valve replacement, cardiac resynchronization therapy, and mitral valve therapeutics. Mitral valve repair involves surgical or minimally invasive procedures to fix a damaged or leaking mitral valve in the heart, aiming to restore its normal function and prevent further complications. The treatment is employed for a variety of indications, including mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation, and is utilized by hospitals, ambulatory surgical centers, and others.
What Is The Mitral Valve Disease Market Size and Share 2026?
The mitral valve disease market size has grown strongly in recent years. It will grow from $3.28 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of heart valve disorders, growing reliance on echocardiography diagnostics, rise in surgical mitral valve repair procedures, adoption of anticoagulation therapies, improved hospital cardiac care infrastructure.What Is The Mitral Valve Disease Market Growth Forecast?
The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion of minimally invasive mitral valve procedures, rising demand for tmvr solutions, growth in remote cardiac monitoring adoption, increasing investment in valve repair devices, development of personalized therapeutic approaches. Major trends in the forecast period include advancements in precision medicine-based mitral valve therapies, integration of ai in mitral valve diagnostics and monitoring, growth of cloud-based cardiac imaging and data platforms, adoption of iot-enabled remote cardiac monitoring devices, increased use of robotic-assisted mitral valve repair systems.
Global Mitral Valve Disease Market Segmentation
1) By Treatment Type: Mitral Valve Repair, Mitral Valve Replacement, Mitral Valve Therapeutics 2) By Indication: Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation 3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Mitral Valve Repair: Surgical Repair, Minimally Invasive Repair, Percutaneous Mitral Valve Repair 2) By Mitral Valve Replacement: Mechanical Valve Replacement, Biological Valve Replacement, Transcatheter Mitral Valve Replacement (TMVR) 3) By Mitral Valve Therapeutics: Pharmacological Treatments, Anticoagulation Therapy, Mitral Valve Repair DevicesWhat Is The Driver Of The Mitral Valve Disease Market?
The increasing prevalence of vascular heart diseases is expected to propel the growth of mitral valve disease market going forward. Vascular heart diseases encompass a group of conditions affecting the blood vessels supplying the heart or within the heart itself. A complex interplay of lifestyle choices, demographic changes, medical conditions, environmental factors, and genetic variables drives the increasing cases of vascular heart diseases. Vascular heart diseases, such as ischemic heart disease and hypertension, can indirectly cause mitral valve disease by compromising the heart's structure and function, leading to conditions that affect the mitral valve. For instance, in November 2024, according to the Scottish Government, a Scotland-based government agency prevalence of any cardiovascular disease among adults rises sharply with age, reaching 42% in those aged 75 and over. Therefore, the increasing prevalence of vascular heart diseases is driving the mitral valve disease industry.Key Players In The Global Mitral Valve Disease Market
Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Mitral Valve Disease Market Trends and Insights
Major companies operating in the mitral valve disease market are developing stented tissue valves to address the growing demand for minimally invasive treatment options. Stented tissue valves are designed to provide durable and reliable performance, offering patients an alternative to traditional surgical interventions. For instance, in April 2024, Medtronic, an Ireland-based healthcare company, launched the Avalus Ultra valve, an advanced surgical aortic tissue valve designed for enhanced ease of use during implantation and long-term patient management. Building on a decade of clinical experience with the original Avalus valve, the Avalus Ultra features a low valve profile for easier implantation, a PEEK base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA) that may promote greater blood flow. Additionally, it includes a radiopaque coil for clear visibility during future valve-in-valve procedures.What Are Latest Mergers And Acquisitions In The Mitral Valve Disease Market?
In July 2024, Edwards Lifesciences, a US-based medical technology company, acquired Innovative Bio Medical Ltd. for an undisclosed amount. This acquisition aims to enhance Edwards Lifesciences' transcatheter mitral valve replacement technologies to better address unmet needs in structural heart disease and support long-term growth. Innovative Bio Medical Ltd. is a UK-based medical device company focused on developing transcatheter mitral valve replacement (TMVR) technologies.
Regional Outlook
Europe was the largest region in the mitral valve disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Mitral Valve Disease Market?
The mitral valve disease market includes revenues earned by entities by providing services such as diagnostic imaging, surgical, and interventional procedures, alongside consultation, rehabilitation, and telemedicine services, catering to patient care and research needs. The market value includes the value of related goods sold by the service provider or included within the service offering. The mitral valve disease market also includes sales of valve repair devices, valve replacement devices, imaging and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Mitral Valve Disease Market Report 2026?
The mitral valve disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mitral valve disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Mitral Valve Disease Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.59 billion |
| Revenue Forecast In 2030 | $5.01 billion |
| Growth Rate | CAGR of 8.6% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Treatment Type, Indication, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |